{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T07:47:36Z","timestamp":1789285656439,"version":"build-2803163510"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejim.2024.07.030","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:02:42Z","timestamp":1722513762000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pulmonary hypertension associated to left heart disease: Phenotypes and treatment"],"prefix":"10.1016","volume":"129","author":[{"given":"Rosalinda","family":"Madonna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ghelardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"D'Alleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.07.030_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2013.10.033","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"Vachi\u00e9ry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0002","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0003","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.113.008461","article-title":"Right ventricular function in heart failure with preserved ejection fraction: a community-based study","volume":"130","author":"Mohammed","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0004","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ejhf.873","article-title":"Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction","volume":"19","author":"Bosch","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004121","article-title":"Load-independent systolic and diastolic right ventricular function in heart failure with preserved ejection fraction as assessed by resting and handgrip exercise pressure-volume loops","volume":"11","author":"Rommel","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0006","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1093\/eurheartj\/ehw241","article-title":"Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction","volume":"37","author":"Borlaug","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0007","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCHEARTFAILURE.114.002114","article-title":"Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction","volume":"8","author":"Andersen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0008","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0009","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0010","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jtcvs.2016.09.017","article-title":"Mitral stenosis with pulmonary hypertension: we should operate early","volume":"153","author":"Yang","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0011","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1136\/hrt.2009.186486","article-title":"Echocardiography predictors and prognostic value of pulmonary artery systolic pressure in chronic organic mitral regurgitation","volume":"96","author":"Le Tourneau","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2024.07.030_bib0012","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijcard.2014.08.072","article-title":"Impact of pre-transplant pulmonary hypertension on survival after heart transplantation: a UNOS registry analysis","volume":"176","author":"Vakil","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0013","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0002-8703(93)90704-D","article-title":"Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience","volume":"126","author":"Murali","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0014","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.chest.2019.07.028","article-title":"Impact of the new pulmonary hypertension definition on heart transplant outcomes: expanding the hemodynamic risk profile","volume":"157","author":"Crawford","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.07.030_bib0016","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ejcts\/ezs678","article-title":"Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension","volume":"43","author":"Kutty","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0017","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtcvs.2006.08.104","article-title":"Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates","volume":"133","author":"Zimpfer","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0018","first-page":"23","article-title":"Mechanical circulatory support is effective to treat pulmonary hypertension in heart transplant candidates disqualified due to unacceptable pulmonary vascular resistance","volume":"15","author":"Zakliczy\u0144ski","year":"2018","journal-title":"Kardiochir Torakochirurgia Pol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0019","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The international society for heart and lung transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2024.07.030_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchf.2014.07.010","article-title":"The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease","volume":"3","author":"Tampakakis","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0022","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.694240","article-title":"Pulmonary hypertension in patients with heart failure with mid-range ejection fraction","volume":"8","author":"Maeder","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-023-10372-9","article-title":"Pulmonary hypertension secondary to valvular heart disease: a state-of-the-art review","author":"Patel","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.07.030_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcmg.2014.12.003","article-title":"Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group","volume":"8","author":"Magne","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.07.030_bib0026","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-814661-3.00003-4","article-title":"Epidemiology of heart valve disease","author":"Huntley","year":"2019","journal-title":"Princ Heart Valve Eng"},{"key":"10.1016\/j.ejim.2024.07.030_bib0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacasi.2022.04.008","article-title":"Pulmonary hypertension definition, classification, and epidemiology in Asia","volume":"2","author":"Anderson","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.ejim.2024.07.030_bib0029","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2021.04.006","article-title":"Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension","volume":"335","author":"Pfeuffer-Jovic","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0031","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.664","article-title":"Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction","volume":"19","author":"Ghio","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0032","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ahj.2017.06.006","article-title":"Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: similarities and disparities","volume":"192","author":"Adir","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0033","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"Vanderpool","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0034","article-title":"The prevalence and survival of pulmonary hypertension due to left heart failure: a retrospective analysis of a multicenter prospective cohort study","volume":"9","author":"Lin","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0035","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jcin.2019.08.031","article-title":"Impact of pulmonary hypertension hemodynamic status on long-term outcome after transcatheter aortic valve replacement","volume":"12","author":"Schewel","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.07.030_bib0036","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjcard.2020.06.037","article-title":"Impact of combined pre and postcapillary pulmonary hypertension on survival after transcatheter aortic valve implantation","volume":"131","author":"Sultan","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0037","unstructured":"Hart S.A., Krasuski R.A., Wang A., Kisslo K., Harrison J.K., Bashore T.M. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis 2010."},{"key":"10.1016\/j.ejim.2024.07.030_bib0038","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2006.11.052","article-title":"Prognostic importance of pulmonary hypertension in patients with heart failure","volume":"99","author":"Kjaergaard","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0039","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hfc.2014.04.008","article-title":"Phenotypic spectrum of heart failure with preserved ejection fraction","volume":"10","author":"Shah","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ejim.2024.07.030_bib0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0041","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ehf2.14368","article-title":"Heart failure with preserved ejection fraction phenogroup classification using machine learning","volume":"10","author":"Kyodo","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0042","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0043","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0044","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0045","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13081218","article-title":"Phenotype-specific outcome and treatment response in heart failure with preserved ejection fraction with comorbid hypertension and diabetes: a 12-month multicentered prospective cohort study","volume":"13","author":"Nguyen","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0047","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","article-title":"Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0048","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0049","doi-asserted-by":"crossref","first-page":"105","DOI":"10.6002\/ect.IAHNCongress.25","article-title":"A story of serendipities: from phlorizin to gliflozins","volume":"21","author":"Helvac\u0131","year":"2023","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.ejim.2024.07.030_bib0050","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","article-title":"Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial","volume":"38","author":"McLaughlin","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2024.07.030_bib0051","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","article-title":"Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy","volume":"75","author":"Al-Omary","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.07.030_bib0052","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00441-016-2539-y","article-title":"Pulmonary vascular remodeling in pulmonary hypertension","volume":"367","author":"Tuder","year":"2017","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0053","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chest.2022.09.040","article-title":"Evidence of advanced pulmonary vascular remodeling in obstructive hypertrophic cardiomyopathy with pulmonary hypertension","volume":"163","author":"Maron","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.07.030_bib0054","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00186.2013","article-title":"Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease","volume":"305","author":"Hunt","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2017.06.053","article-title":"Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats","volume":"154","author":"Fujimoto","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235884","article-title":"The biological bases of group 2 pulmonary hypertension","volume":"20","author":"Fern\u00e1ndez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2024.07.030_bib0057","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jare.2021.11.011","article-title":"Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt\/\u03b2-catenin pathway","volume":"40","author":"Lei","year":"2022","journal-title":"J Adv Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0058","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0059","article-title":"Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC\/MAPK pathway and the expression of IL-6 and TNF-\u03b1","volume":"16","author":"Huang","year":"2021","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lfs.2018.12.056","article-title":"Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure","volume":"219","author":"Zhang","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.ejim.2024.07.030_bib0061","article-title":"Mechanical stretching of pulmonary vein stimulates matrix metalloproteinase-9 and transforming growth factor-\u03b21 through stretch-activated channel\/MAPK pathways in pulmonary hypertension due to left heart disease model rats","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2024.07.030_bib0062","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezs445","article-title":"Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats","volume":"42","author":"Yao","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejim.2024.07.030_bib0063","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1093\/cvr\/cvab016","article-title":"Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload","volume":"117","author":"Lambert","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0064","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ppul.23610","article-title":"Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase","volume":"52","author":"Chen","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.098","article-title":"Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice","volume":"216","author":"Pradhan","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/children10020270","article-title":"Safety and efficacy of sildenafil for group 2 pulmonary hypertension in left heart failure","volume":"10","author":"Desai","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.ejim.2024.07.030_bib0067","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1002\/ehf2.14515","article-title":"Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left-sided heart diseases","volume":"10","author":"Satoh","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0068","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachi\u00e9ry","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0069","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.07.030_bib0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-60761-500-2_19","article-title":"Rho kinase-mediated vasoconstriction in pulmonary hypertension","volume":"661","author":"McMurtry","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0071","first-page":"1341","article-title":"Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease","volume":"42","author":"Zhuang","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0072","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1879-3111","article-title":"The therapeutic role of rho kinase inhibitor, fasudil, on pulmonary hypertension; a systematic review and meta-analysis","volume":"73","author":"Abedi","year":"2023","journal-title":"Drug Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0073","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2020.07.008","article-title":"Systolic overload-induced pulmonary inflammation, fibrosis, oxidative stress and heart failure progression through interleukin-1\u03b2","volume":"146","author":"Shang","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0074","doi-asserted-by":"crossref","first-page":"H980","DOI":"10.1152\/ajpheart.00520.2020","article-title":"Hypoxia-induced inhibition of mTORC1 activity in the developing lung: a possible mechanism for the developmental programming of pulmonary hypertension","volume":"320","author":"Mundo","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0075","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1113\/JP275987","article-title":"Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin","volume":"597","author":"van Duin","year":"2019","journal-title":"J Physiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0076","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217745019","article-title":"The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension","volume":"8","author":"Meoli","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ejim.2024.07.030_bib0077","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"L\u00fcscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0078","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11899-016-0347-9","article-title":"Activin receptor II ligand traps and their therapeutic potential in myelodysplastic syndromes with ring sideroblasts","volume":"11","author":"Mies","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ejim.2024.07.030_bib0079","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/molehr\/gam055","article-title":"Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein","volume":"13","author":"Li","year":"2007","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.ejim.2024.07.030_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1064290","article-title":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure","volume":"10","author":"Joshi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0081","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/ehf2.14148","article-title":"Elevated plasma WIF-1 levels are associated with worse prognosis in heart failure with pulmonary hypertension","volume":"9","author":"Kania","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0082","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2741\/4477","article-title":"Molecular strategies for modulating Wnt signaling","volume":"22","author":"Gustafson","year":"2017","journal-title":"Front Biosci"},{"key":"10.1016\/j.ejim.2024.07.030_bib0083","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.CIR.0000141802.29945.34","article-title":"Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia\/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide","volume":"110","author":"Hobbs","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0084","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.peptides.2004.09.023","article-title":"Natriuretic peptide receptor-C signaling and regulation","volume":"26","author":"Anand-Srivastava","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.ejim.2024.07.030_bib0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2018.06.001","article-title":"Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure","volume":"281","author":"Egom","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0086","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccc.2023.05.003","article-title":"Diagnosis and management of pulmonary hypertension and right ventricular failure in the cardiovascular intensive care unit","volume":"40","author":"Vaidy","year":"2024","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ejim.2024.07.030_bib0087","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14797\/RKQN5397","article-title":"Management of pulmonary hypertension in left heart disease","volume":"17","author":"Macera","year":"2021","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0088","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world symposium on pulmonary hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0089","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0091","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0092","series-title":"SERENADE: Macitentan fails in HFpEF plus PAH","author":"Voors","year":"2022"},{"key":"10.1016\/j.ejim.2024.07.030_bib0093","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0094","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1055\/s-0043-1770118","article-title":"Management of pulmonary arterial hypertension","volume":"44","author":"Weatherald","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","article-title":"Effects of 5\u2019-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial","volume":"14","author":"Behling","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0096","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0097","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/eurjhf\/hfr147","article-title":"Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study","volume":"14","author":"Guazzi","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0098","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0099","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/chf.12008","article-title":"Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?","volume":"19","author":"Amin","year":"2013","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0101","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.07.030_bib0102","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0103","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-020-01671-2","article-title":"Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study","volume":"20","author":"Belyavskiy","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2024.07.030_bib0104","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0735-1097(17)34068-8","article-title":"Low urinary cgmp\/bnp ratio is associated with worse outcomes in heart failure but is increased by treatment with sacubitril\/valsartan: an analysis of paradigm-HF","volume":"69","author":"Jhund","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0106","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0107","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0108","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0109","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0110","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0111","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.07.030_bib0112","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.07.030_bib0113","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.07.030_bib0114","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/S0002-9149(99)80381-6","article-title":"Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group","volume":"75","author":"Sueta","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0116","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0118","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjcard.2018.01.006","article-title":"Effect of optimizing guideline-directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction","volume":"121","author":"Yamaguchi","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0119","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0120","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.07.030_bib0121","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021682","article-title":"Trends in premature mortality from acute myocardial infarction in the United States, 1999 to 2019","volume":"11","author":"Dani","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.07.030_bib0122","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejim.2024.07.030_bib0123","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2020.108701","article-title":"An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension","volume":"163","author":"Abdel Ghafar","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.ejim.2024.07.030_bib0125","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/092986711796642562","article-title":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome","volume":"18","author":"Kaparianos","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ejim.2024.07.030_bib0126","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/thorax.58.7.629","article-title":"Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study","volume":"58","author":"Kanazawa","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.ejim.2024.07.030_bib0127","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1161\/01.CIR.94.8.1941","article-title":"Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling","volume":"94","author":"Nong","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1378\/chest.109.2.424","article-title":"Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans","volume":"109","author":"Cargill","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.07.030_bib0129","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1161\/01.CIR.0000031735.86021.79","article-title":"Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure","volume":"106","author":"Abraham","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0130","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00348-2021","article-title":"Treatment of pulmonary hypertension associated with COPD: a systematic review","volume":"8","author":"Arif","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejim.2024.07.030_bib0131","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.108.125468","article-title":"Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer","volume":"54","author":"Yamazato","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.07.030_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-801364-9.00025-0","article-title":"ACE2 cell biology, regulation, and physiological functions","volume":"185","author":"Turner","year":"2015","journal-title":"Prot Arm Renin Angiotensin Syst (RAS)"},{"key":"10.1016\/j.ejim.2024.07.030_bib0133","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.chest.2020.09.258","article-title":"Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension: insights from the veterans affairs clinical assessment reporting and tracking database","volume":"159","author":"Lahm","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.07.030_bib0134","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jacc.2003.09.051","article-title":"Clinical significance of brain natriuretic peptide in primary pulmonary hypertension","volume":"43","author":"Leuchte","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0135","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ehf2.13225","article-title":"Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction","volume":"8","author":"Tran","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0136","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.734697","article-title":"Reduction of pulmonary hypertension after transition to sacubitril\/valsartan in patients with heart failure with preserved ejection fraction","volume":"8","author":"Burgdorf","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10554-020-01973-8","article-title":"Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction","volume":"37","author":"Yener\u00e7a\u011f","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.07.030_bib0138","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024449","article-title":"Effect of sacubitril\/valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies","volume":"11","author":"Zhang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.07.030_bib0139","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/FJC.0000000000001477","article-title":"Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril\/valsartan in patients with heart failure with preserved ejection fraction","volume":"82","author":"Brockm\u00f6ller","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ehf2.13665","article-title":"Less loop diuretic use in patients on sacubitril\/valsartan undergoing remote pulmonary artery pressure monitoring","volume":"9","author":"B\u00f6hm","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0141","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"Codina","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0142","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1164\/rccm.201003-0335OC","article-title":"Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats","volume":"182","author":"Bogaard","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0143","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1388-9842(03)00054-0","article-title":"Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol","volume":"5","author":"Nodari","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0144","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/HYPERTENSIONAHA.120.16196","article-title":"Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells","volume":"78","author":"Kowalski","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.07.030_bib0145","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00300.2012","article-title":"Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension","volume":"304","author":"Preston","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0146","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)","volume":"112","author":"Maron","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0147","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2019.02.014","article-title":"Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure\u2013a danish nationwide registry-based study","volume":"63","author":"Andersson","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107987","article-title":"Mineralocorticoid receptors in pulmonary hypertension and right heart failure: from molecular biology to therapeutic targeting","volume":"231","author":"Mamazhakypov","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejim.2024.07.030_bib0149","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0150","article-title":"Obesity is associated with pulmonary hypertension and modifies outcomes","volume":"9","author":"Frank","year":"2020","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"10.1016\/j.ejim.2024.07.030_bib0151","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients - a randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0152","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.07.030_bib0153","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00392-021-01954-4","article-title":"SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure-further evidence for improved hemodynamics by continuous pressure monitoring","volume":"111","author":"Kirschbaum","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0154","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58081128","article-title":"Effects of sodium-glucose co-transporter-2 inhibition on pulmonary arterial stiffness and right ventricular function in heart failure with reduced ejection fraction","volume":"58","author":"\u00c7amc\u0131","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.ejim.2024.07.030_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110686","article-title":"Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: a pilot prospective study. GLISCAR study","volume":"200","author":"Palmiero","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejim.2024.07.030_bib0156","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0157","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2024.07.030_bib0158","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.07.030_bib0159","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0160","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0161","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cardfail.2014.10.012","article-title":"Association of anti-diabetic medications targeting the glucagon-like peptide-1 pathway and heart failure events in patients with diabetes","volume":"21","author":"Velez","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0162","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0163","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107180","article-title":"The future of group 2 pulmonary hypertension: exploring clinical trials and therapeutic targets","volume":"151","author":"Awada","year":"2023","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0164","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","article-title":"Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension","volume":"283","author":"Kramer","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0165","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0166","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2006.06.052","article-title":"Effects of levosimendan on right ventricular function in patients with advanced heart failure","volume":"98","author":"Parissis","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0167","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00059-008-3051-2","article-title":"Safety and effectiveness of levosimendan in patients with predominant right heart failure","volume":"33","author":"Poelzl","year":"2008","journal-title":"Herz"},{"key":"10.1016\/j.ejim.2024.07.030_bib0168","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/FJC.0000000000001332","article-title":"Milrinone versus sildenafil in treatment of neonatal persistent pulmonary hypertension: a randomized control trial","volume":"80","author":"Imam","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0169","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(21)01914-0","article-title":"To master heart failure, first master congestion","volume":"398","author":"Cleland","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.07.030_bib0170","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ejhf.2664","article-title":"Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology","volume":"24","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0171","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0735-1097(90)90174-N","article-title":"Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure","volume":"15","author":"Gibbs","year":"1990","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ejim.2024.07.030_bib0172","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial","volume":"29","author":"ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0173","article-title":"Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study","volume":"17","author":"Dauw","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0174","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.07.030_bib0175","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","article-title":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial","volume":"401","author":"Brugts","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.07.030_bib0176","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ejhf.2656","article-title":"Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study","volume":"24","author":"Assmus","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0177","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0178","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.07.030_bib0179","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cardfail.2016.09.012","article-title":"Hemodynamic monitoring in advanced heart failure: results from the LAPTOP-HF trial","volume":"22","author":"Abraham","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jacc.2023.11.030","article-title":"Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction","volume":"83","author":"Lindenfeld","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0181","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0182","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.07.030_bib0183","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/jcm8101757","article-title":"Comparison of hemodynamic factors predicting prognosis in heart failure: a systematic review","volume":"8","author":"Aalders","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0184","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCHEARTFAILURE.111.963785","article-title":"What is the prognostic significance of pulmonary hypertension in heart failure?","volume":"4","author":"Chatterjee","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in World Health Organization Group II Pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction\u2013induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0186","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004843","article-title":"Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review","volume":"4","author":"Dzudie","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2024.07.030_bib0187","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cjco.2023.05.011","article-title":"Right ventricular systolic pressure trajectory as a predictor of hospitalization and mortality in patients with chronic heart failure","volume":"5","author":"Kotrri","year":"2023","journal-title":"CJC Open"},{"key":"10.1016\/j.ejim.2024.07.030_bib0188","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4250\/jcvi.2019.27.e36","article-title":"Improvement of left ventricular ejection fraction and pulmonary hypertension are significant prognostic factors in heart failure with reduced ejection fraction patients","volume":"27","author":"Kwon","year":"2019","journal-title":"J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.07.030_bib0189","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ejhf.1862","article-title":"Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors","volume":"22","author":"Santiago-Vacas","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00392-021-01954-4","article-title":"SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure\u2014Further evidence for improved hemodynamics by continuous pressure monitoring","volume":"111","author":"Kirschbaum","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2024.07.030_bib0191","article-title":"Benefits of remote hemodynamic monitoring in heart failure","author":"Clephas","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.07.030_bib0192","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ejhf.2869","article-title":"Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR-HF trial","volume":"25","author":"D'Amario","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.07.030_bib0193","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837","article-title":"Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study","volume":"8","author":"Chen","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.07.030_bib0194","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","article-title":"Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study","volume":"12","author":"Zhang","year":"2019","journal-title":"JACC Cardiovasc Interv"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524003261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524003261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T01:37:17Z","timestamp":1730597837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524003261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":194,"alternative-id":["S0953620524003261"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.030","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary hypertension associated to left heart disease: Phenotypes and treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}